Exscientia raises $100m Series C funding to develop fully autonomous drug design
Exscientia has raised $100m in its second Series C in the past nine months. The round was led by BlackRock,…
By
Venture Capital
Latest in
Venture Capital
Imcyse closes €21.3m Series B as new partner Pfizer takes equity stake
Imcyse has raised €21.3m in a Series B round, which includes an equity purchase by new partner Pfizer. The Belgian…
By
TCR-T cell therapies for cancer: TScan raises $100m in Series C round
New and existing investors have supported TCR therapy-focused TScan with $100m in an oversubscribed Series C round. The money will…
By
Disease-cancelling drugs: Immuneering raises $62m in Series B round
Immuneering has raised $62m in an oversubscribed Series B round led by high-profile life science investors. The money will be…
By
Spotlight on rare neurological diseases: Noema closes $60.8m Series A round
Rare neurological disease-focused Noema has raised CHF54m ($60.8m) in a Series A round. The company plans to use the funding…
By
Investing in innovative biotechs with Novo Ventures
Despite the Covid-19 pandemic, Novo Ventures, the venture capital arm of the Novo Nordisk Foundation's Novo Holdings, has made 18…
By
SynOx raises €37m in Series A to develop emactuzumab for rare cancer TGCT
Celleron spin-out SynOx has closed a €37m Series A funding round led by HealthCap and Medicxi. The funding will be…
By
Araris raises CHF15.2m to support its next-gen ADCs
Araris has closed a CHF15.2m seed round to support the advancement of its pipeline of ADC drugs for unmet needs…
By